BlackRock Institutional Trust’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

BlackRock Institutional Trust’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$67.7M	Buy	4,181,628 +124,532	+3%	+$2.26M	0.01%	1149
2016 Q3	$73.6M	Buy	4,057,096 +383,892	+10%	+$7.5M	0.01%	1052
2016 Q2	$60.5M	Buy	3,673,204 +1,335,251	+57%	+$21.6M	0.01%	1120
2016 Q1	$38.7M	Buy	2,337,953 +61,457	+3%	+$1.08M	0.01%	1389
2015 Q4	$49.3M	Sell	2,276,496 -1,438	-0.1%	-$28K	0.01%	1251
2015 Q3	$45.1M	Buy	2,277,934 +123,539	+6%	+$3.9M	0.01%	1284
2015 Q2	$74.8M	Buy	+2,154,395	New	+$65.7M	0.01%	1074
2014 Q3	–	Sell	-795,804	Closed	-$12.6M	–	3981
2014 Q2	$12.6M	Buy	795,804 +132,112	+20%	+$1.89M	﹤0.01%	2284
2014 Q1	$10M	Buy	663,692 +79,011	+14%	+$892K	﹤0.01%	2422
2013 Q4	$4.46M	Sell	584,681 -37,825	-6%	-$204K	﹤0.01%	2841
2013 Q3	$2.08M	Buy	622,506 +60,485	+11%	+$159K	﹤0.01%	3114
2013 Q2	$1.38M	Buy	+562,021	New	+$1.35M	﹤0.01%	3229

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock Institutional Trust's HZNP Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 3.1% in Q4 2016, buying an estimated $2.26M and bringing the position to 4,181,628 shares worth $67.7M. The position accounts for 0.01% of the portfolio, ranked #1149.

BlackRock Institutional Trust first reported a position in HZNP in Q2 2013 and has held it in 12 quarters since. The position peaked at $74.8M in Q2 2015. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

BlackRock Institutional Trust held 4,181,628 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $67.7M as of Q4 2016.
BlackRock Institutional Trust bought 124,532 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $2.26M.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #1149 holding.
BlackRock Institutional Trust first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and has held it in 12 quarters since.
BlackRock Institutional Trust's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $74.8M in Q2 2015.
234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.